Skip to main content
J.B. Chemicals & Pharmaceuticals Lt logo

J.B. Chemicals & Pharmaceuticals Lt — Investor Relations & Filings

Ticker · JBCHEPHARM ISIN · INE572A01036 BSE.NS Manufacturing
Open in API
Filings indexed 1,770 across all filing types
Latest filing 2026-05-13 Call Transcript
Country IN India
Listing BSE.NS JBCHEPHARM

About J.B. Chemicals & Pharmaceuticals Lt

https://jbpharma.com/

J.B. Chemicals & Pharmaceuticals Ltd, operating as JB Pharma, specializes in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations and active pharmaceutical ingredients. The company holds a strong market position in therapeutic areas including cardiology, gastroenterology, anti-infectives, and dermatology. Its product portfolio features prominent brands such as Cilacar, Metrogyl, and Rantac. With a focus on high-quality production, the organization operates multiple manufacturing sites that comply with global regulatory standards. JB Pharma serves a broad international client base across regions such as Russia, the CIS, Southeast Asia, and Africa, leveraging its research and development capabilities to provide specialized healthcare solutions and maintain a competitive edge in global markets.

Recent filings

Filing Released Lang Actions
Transcript
Call Transcript Classification · 95% confidence The document is the full transcript of a Q4 FY’26 earnings conference call including presenters, financial discussion, and a Q&A session with analysts. It is clearly a call transcript rather than an earnings release or interim report. Therefore, it should be classified as a Call Transcript (CT).
2026-05-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 82% confidence The document is a formal disclosure under SEBI Listing Regulations informing the stock exchange that the audio recording of the Q4 FY26 investors/analysts conference call is now available via a website link. It does not contain the call transcript itself, nor substantive financial data or report content. It is a compliance/regulatory announcement rather than an actual report or transcript. Therefore, it falls under the general “Regulatory Filings” category (RNS), used for miscellaneous regulatory announcements under Listing Obligations and Disclosure Requirements.
2026-05-12 English
Audio recording of Investors/analysts call with Management
Regulatory Filings Classification · 96% confidence The document is a formal exchange filing under SEBI Listing Regulations notifying the availability of an audio recording of the investors/analysts conference call for Q4 FY26 results. It does not contain actual financial data, transcripts, or substantive presentation materials; rather, it is a regulatory disclosure notice. It is neither the conference call transcript (CT) nor an investor presentation (IP) nor a report itself. Therefore, it falls into the fallback category of general regulatory announcements (RNS).
2026-05-12 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 75% confidence The document is a composite of multiple stock‐exchange filings from Indian listed companies, each providing audited financial results for the quarter and year ended March 31, 2026. These filings include actual financial statement figures (standalone and consolidated results), have been reviewed by audit committees, and reference Regulation 33 of the SEBI LODR Regulations—typical of quarterly financial results announcements rather than full annual reports or simple news releases. Under the defined categories, detailed period‐end financial statements for a quarter (including Q4 year‐end) fit “Interim / Quarterly Report (IR)” rather than an Annual Report (10-K), earnings highlights only (ER), or a pure announcement (RPA/RNS). FY 2026
2026-05-12 English
Newspaper advertisement pertaining to financial results for the quarter and year ended March 31, 2026
Regulatory Filings Classification · 65% confidence The provided text is not a cohesive annual or interim report but rather a compendium of multiple short SEBI/stock exchange disclosures: newspaper advertisements of financial results under Reg.47, statements of audited standalone and consolidated results under Reg.33, a notice to debenture holders, etc. These are compliance/regulatory announcements rather than full financial reports (10-K, IR) or specialized filings. Therefore, the appropriate category is the fallback “Regulatory Filings” (RNS).
2026-05-12 English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details ....
Regulatory Filings Classification · 82% confidence The document is a compliance letter submitted to the stock exchange under a SEBI circular confirming the company’s status (not a ‘Large Corporate’) for debt security issuance. It does not contain financial statements or actual fundraising details, nor is it an actual report or call transcript. It is a general regulatory submission/fallback announcement, best fitting the Regulatory Filings category (RNS).
2026-05-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.